Tirzepatide
Sold as Mounjaro (type 2 diabetes) and Zepbound (weight and sleep apnea)

Tirzepatide is a GIP and GLP-1 receptor agonist, the drug inside Mounjaro and Zepbound. It is FDA-approved for type 2 diabetes, for lowering heart risk in type 2 diabetes, for chronic weight management, and for moderate-to-severe obstructive sleep apnea with obesity. In SURMOUNT-1, people on 15 mg lost 20.9% of body weight over 72 weeks, vs 3.1% on placebo.5 Nausea and other stomach effects are common.6
Compared head to head with semaglutide in SURMOUNT-5.7 See semaglutide vs tirzepatide, or all three GLP-1 drugs in the comparison hub.
In this guide
At a glance
| What it is | A peptide based on the GIP sequence, with a fatty diacid that binds albumin, so one dose lasts a week. It activates both GIP and GLP-1 receptors6 |
|---|---|
| Sold as | Weekly injections only: single-dose pen, single-dose or multi-dose vial, and a multi-dose KwikPen (both labels list one)6, 8 |
| Approved for | Type 2 diabetes in adults and children 10 and older; lowering heart risk in type 2 diabetes (Mounjaro). Chronic weight management; sleep apnea with obesity (Zepbound)8, 2, 6 |
| Not approved for | Heart failure, kidney disease or MASH9, 8, 6 |
| Best evidence | Large trials, including SURPASS-CVOT (n=13,299) and SURMOUNT-1 (n=2,539)10, 5 |
| Weight loss in trials | −20.9% at 72 weeks on 15 mg (SURMOUNT-1)5; −20.2% vs −13.7% on semaglutide head to head (SURMOUNT-5)7 |
| Main risks | Nausea (25% to 29% on Zepbound vs 8% on placebo), diarrhea, vomiting, constipation. Boxed warning for thyroid C-cell tumors seen in rats6 |
| Typical cost | Zepbound vial or KwikPen $299 to $449 a month self-pay, by dose; Mounjaro $499 a month11, 12 |
Where to get it
MoveWell sells nothing. All options and prices
Vials or multi-dose KwikPen: $299 (2.5 mg), $399 (5 mg) and $449 (7.5 to 15 mg) a month if you refill within 45 days. You still need a prescription.11
See Zepbound self-pay pricingSingle-dose pen: $499 a month, all doses. Prescription needed.12
See Mounjaro self-pay pricingAny licensed prescriber can prescribe either brand. The Zepbound single-dose pen is for insured patients, "as low as $25" with commercial coverage.11 Coverage depends on your plan and diagnosis.
Insurance and other optionsNot listed: compounded copies and "research use only" vials. Why
Molecular structure
A peptide based on the GIP sequence. The label names three kinds of change: Aib (a non-standard amino acid) at positions 2 and 13, a C-terminal amide, and a C20 fatty diacid linked to Lys20 that binds albumin.6 The diagram shows only those label-confirmed features, not every residue.
Lys20 and its C20 fatty diacid side chain, which binds albumin
- Class
- GIP and GLP-1 receptor agonist
- Formula
- C225H348N48O68 (label)
- Weight
- 4813.53 Da (label)
- Half-life
- About 5 to 6 days
- Length
- 39 amino acids Unverified
- CAS
- 2023788-19-2 Unverified
Formula, weight, half-life and the modifications are from the Zepbound label.6 The label does not state the amino-acid count. The length and CAS number come from a secondary source and are unconfirmed.13
Brands and approvals
Tirzepatide is sold as two brands. Both contain the same molecule and use the same doses; they differ in what they're approved for.
| Product | Approved for | Form | Dose range | Approved |
|---|---|---|---|---|
| Mounjaro | Blood sugar in type 2 diabetes, adults and children 10 and older8; lowering the risk of major heart events (heart death, heart attack, stroke) in adults with type 2 diabetes at high risk of them8, 2 | Weekly injection: single-dose pen or vial; multi-dose vial on the market from Jan 202614; the label also lists a single-patient-use KwikPen with 4 doses8 | 2.5 to 15 mg (children: up to 10 mg) | May 13, 2022 (diabetes)15; children 10 and up, label updated Dec 2025 (FDA goal date December 19, 2025; exact action date Unverified)8, 16, 17; August 28, 2026 (heart risk)2 |
| Zepbound | Chronic weight management in adults with obesity, or overweight with at least one weight-related condition; moderate-to-severe obstructive sleep apnea in adults with obesity6 | Weekly injection: single-dose pen, single-dose or multi-dose vial, multi-dose KwikPen6 | 2.5 to 15 mg | November 8, 2023 (weight)18; December 20, 2024 (sleep apnea, the first drug approved for it)19 |
Mounjaro's heart-risk indication is worded as in its 08/2026 label.8 Zepbound vials (August 27, 2024) and the KwikPen (February 23, 2026) launch dates come from a secondary timeline Unverified.20
What it is not approved for
- Heart failure. Not approved in the US. Lilly withdrew its application for heart failure with preserved ejection fraction (HFpEF) after FDA "indicated an additional confirmatory clinical trial is required."9 In Jan 2026, Europe's regulator also declined a separate heart-failure indication, citing no reduction in heart death and uncertainty about whether the benefit was independent of weight loss.21
- Kidney disease. No kidney indication. The label needs no dose change for kidney impairment and carries a warning for acute kidney injury.8
- Use with other GLP-1 drugs. The Zepbound label says using it with other tirzepatide products or any GLP-1 receptor agonist is not recommended.6
How it works
Tirzepatide "selectively binds to and activates both the GIP and GLP-1 receptors," the two gut hormones that help control blood sugar and appetite.6 When FDA approved Mounjaro in 2022, it called the drug the first to activate both.15
- Aib at positions 2 and 13. Non-standard amino acids in the chain, part of the label's description of the molecule.6
- Fatty diacid on Lys20. A C20 diacid that binds albumin in the blood, which gives a half-life of about 5 to 6 days and once-weekly dosing.6
- Injection only. Every labeled form is a weekly injection under the skin. There is no tirzepatide pill.6, 8
Evidence map
Each use is graded separately. Four are FDA-approved indications backed by large trials.
FDA-approved (Zepbound): SURMOUNT-1 (n=2,539), SURMOUNT-2 (n=938), SURMOUNT-3 (n=579), SURMOUNT-4 (n=670)
FDA-approved (Mounjaro) since 2022: SURPASS-2 (n=1,879), SURPASS-PEDS (n=99)
FDA-approved (Mounjaro, August 28, 2026): SURPASS-CVOT (n=13,299)
FDA-approved (Zepbound): SURMOUNT-OSA (n=469)
Strong human: SUMMIT (n=731). Not approved; US application withdrawn
Scale: 5 FDA-approved, 4 strong human, 3 limited human, 2 animal or lab only, 1 anecdotal
Key studies
| Use | Study | Model | Finding |
|---|---|---|---|
| Weight | SURMOUNT-15 | Human RCT n=2,539 | Obesity without diabetes, 72 weeks: −15.0%, −19.5% and −20.9% (5, 10, 15 mg) vs −3.1% on placebo. 57% on 15 mg lost at least 20%, vs 3% |
| Weight with type 2 diabetes | SURMOUNT-222 | Human RCT n=938 | 72 weeks: −12.8% (10 mg) and −14.7% (15 mg) vs −3.2%. A1C −2.07 and −2.08 points vs −0.51 |
| Weight after diet and exercise | SURMOUNT-323, 24 | Human RCT n=579 | After a 12-week lifestyle program, a further −18.4% vs +2.5% on placebo over 72 weeks |
| Keeping weight off | SURMOUNT-425, 24 | Human RCT n=670 | After about 21% loss in a 36-week lead-in, staying on it gave a further −5.5%; switching to placebo regained 14.0% over 52 weeks |
| Weight, head to head | SURMOUNT-57 | Human RCT n=751 | vs semaglutide, open label, 72 weeks: −20.2% vs −13.7%; waist −18.4 vs −13.0 cm |
| Sleep apnea | SURMOUNT-OSA26 | Human RCT n=469 | 52 weeks: breathing events −25.3 vs −5.3 per hour without CPAP, and −29.3 vs −5.5 with CPAP |
| Heart | SURPASS-CVOT10 | Human RCT n=13,299 | vs dulaglutide in type 2 diabetes with heart disease, median about 4 years: major heart events 12.2% vs 13.1%, HR 0.92 (95.3% CI 0.83–1.01). Non-inferior; superiority not shown. Death from any cause HR 0.84 |
| Heart failure | SUMMIT27 | Human RCT n=731 | HFpEF with obesity: heart death or worsening heart failure 9.9% vs 15.3%, HR 0.62. Heart death alone 2.2% vs 1.4%, not significant |
| Type 2 diabetes, head to head | SURPASS-228, 29 | Human RCT n=1,879 | vs semaglutide 1 mg, open label, 40 weeks: A1C −2.01 to −2.30 points vs −1.86. Tirzepatide arms lost 1.9 to 5.5 kg more |
| Type 2 diabetes, children | SURPASS-PEDS30 | Human RCT n=99 | Ages 10 and up, 30 weeks: A1C −2.2 points (pooled doses) from 8.04% |
SURMOUNT-1's headline figures use the treatment-regimen estimand, which counts everyone randomized whether or not they kept taking the drug.5 Numbers from separate trials can't be ranked against each other.
Pick a goal
Pick your goal to see which approved product fits and what the evidence shows.
Approved vs compounded
During the shortage, pharmacies could legally make copies of tirzepatide. FDA found the shortage resolved on October 2, 2024, and confirmed it on December 19, 2024. Compounding pharmacies (503A) had until February 18, 2025, and outsourcing facilities (503B) until March 19, 2025, to stop.1
Compounders sued. On August 27, 2026, the Fifth Circuit affirmed judgment for FDA and Lilly (Outsourcing Facilities Ass'n v. FDA, No. 25-10600, unpublished). It found no harm from how FDA handled notice and comment, and held that FDA reasonably relied on Lilly's supply data over screenshots, surveys and news stories.3
| FDA-approved brand | Compounded | "Research use only" | |
|---|---|---|---|
| FDA review | Safety, effectiveness and quality reviewed | None before sale31 | None |
| Status now | Prescription drug | Routine copies no longer allowed since the shortage ended1, 3 | Sold without a prescription or FDA review |
| Ingredient source | Lilly | Imported bulk tirzepatide is subject to detention unless the maker is on FDA's "Green List"32 | Unknown |
Compounded is not generic
On March 3, 2026, FDA announced warning letters to 30 telehealth companies over illegal marketing of compounded GLP-1 drugs. Its release says compounded drugs are "not FDA-approved" and "not the same as generic drugs."31
Imported ingredients
Since September 19, 2025, Import Alert 66-80 lets FDA detain bulk GLP-1 ingredients, including tirzepatide, from makers not on its "Green List." FDA found 21% of 48 GLP-1 ingredient sites noncompliant. The alert was last revised on October 9, 2026.32, 33
FDA's later actions on compounded tirzepatide, including the 503B bulks-list proposal and warning letters over added-vitamin versions and "research use only" sellers, are on the peptide regulatory tracker.
Label dosing
These are the FDA label schedules, for reference. Your prescriber sets your dose. Both brands start at 2.5 mg. Zepbound steps up on a set schedule; Mounjaro goes up only if more blood sugar control is needed.
Zepbound (weekly)
| When | Weekly dose |
|---|---|
| Weeks 1–4 | 2.5 mg, to start only (not a maintenance dose) |
| Week 5 on | 5 mg |
| Increases | Up 2.5 mg at a time, after at least 4 weeks on the current dose |
| Maintenance, weight | 5, 10 or 15 mg |
| Maintenance, sleep apnea | 10 or 15 mg |
| Maximum | 15 mg |
Source: Zepbound label.6
Mounjaro (weekly)
| When | Weekly dose |
|---|---|
| Start | 2.5 mg |
| Increases | Only if more blood sugar control is needed: up 2.5 mg at a time, after at least 4 weeks on the current dose |
| Maximum | 15 mg in adults; 10 mg in children 10 and older |
Source: Mounjaro label (revised 08/2026), which sets no fixed step to 5 mg.8
Forms
- Single-dose pen or single-dose vial: 2.5, 5, 7.5, 10, 12.5 or 15 mg per 0.5 mL, both brands.6, 8
- Multi-dose vial: 4 doses per vial.6, 14
- KwikPen: a multi-dose pen with 4 doses, listed on both labels. Both say never to share one between patients.6, 8
- Vials need needles and syringes bought separately.11
Side effects and who should avoid it
Label warnings
The labels list warnings for serious allergic (hypersensitivity) reactions, pancreatitis, gallbladder disease, low blood sugar when used with insulin or insulin secretagogues, acute kidney injury, diabetic eye complications in type 2 diabetes, and inhaling stomach contents under anesthesia or deep sedation.6, 8 In Feb 2026, the Zepbound label added a warning for severe stomach and bowel reactions and removed the warning on suicidal behavior and ideation.6 Mounjaro's label added the severe stomach and bowel reactions warning in Dec 2025.8
Common side effects
Reactions in the Zepbound weight trials, by dose, compared with placebo.6
| Reaction | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Nausea | 8% | 25% | 29% | 28% |
| Diarrhea | 8% | 19% | 21% | 23% |
| Vomiting | 2% | 8% | 11% | 13% |
| Constipation | 5% | 17% | 14% | 11% |
| Abdominal pain | 5% | 9% | 9% | 10% |
| Indigestion | 4% | 9% | 9% | 10% |
| Injection-site reactions | 2% | 6% | 8% | 8% |
| Fatigue | 3% | 5% | 6% | 7% |
| Allergic reactions | 3% | 5% | 5% | 5% |
| Belching | 1% | 4% | 5% | 5% |
| Hair loss | 1% | 5% | 4% | 5% |
| Reflux (GERD) | 2% | 4% | 4% | 5% |
| Dizziness | 2% | 4% | 5% | 4% |
| Low blood pressure | 0% | 1% | 1% | 2% |
In people with type 2 diabetes on Mounjaro, rates were lower: nausea 12% to 18% vs 4% on placebo, diarrhea 12% to 17% vs 9%, decreased appetite 5% to 11% vs 1%.8 In SURMOUNT-1, 4.3%, 7.1% and 6.2% stopped for side effects (5, 10, 15 mg) vs 2.6% on placebo.5
Other things to know
- Stopping. In SURMOUNT-4, people switched to placebo after 36 weeks regained 14.0% of body weight over the next year; 89.5% of those who stayed on it kept at least 80% of their loss, vs 16.6%.25, 24
- Hair loss. 4% to 5% on Zepbound vs 1% on placebo.6
- Shared pens. The KwikPen is for one patient only.6, 8
Compared with
| Semaglutide | Tirzepatide | Retatrutide | |
|---|---|---|---|
| Targets | GLP-134 | GIP and GLP-16 | GIP, GLP-1 and glucagon35 |
| Status | FDA-approved (Ozempic, Wegovy, Rybelsus)34 | FDA-approved (Mounjaro, Zepbound)15, 18 | Not approved; filing planned Q1 202736 |
| Taken | Weekly injection or daily tablet34 | Weekly injection only6 | Weekly injection, in trials only37 |
| Weight loss, main trial | −14.9% vs −2.4% at 68 weeks (STEP 1)38 | −20.9% vs −3.1% at 72 weeks (SURMOUNT-1)5 | −25.0% vs −3.9% at 80 weeks (TRIUMPH-1, NEJM)39 |
| Head to head | SURMOUNT-5: tirzepatide −20.2% vs semaglutide −13.7%7 | Not yet compared with tirzepatide; TRIUMPH-5 is ongoing40 | |
Only SURMOUNT-5 compared tirzepatide with another drug for weight. Other numbers come from separate trials with different lengths, populations and analysis methods, so they can't be ranked one to one.41 Full side-by-sides: semaglutide vs tirzepatide, tirzepatide vs retatrutide and the three-way comparison.
Myths vs evidence
All options and prices
MoveWell sells nothing. Prices are dated because they change often
Zepbound self-pay (LillyDirect)
The lower price applies when you refill within 45 days.11
| Dose | Vial or KwikPen | No refill within 45 days |
|---|---|---|
| 2.5 mg (starting dose) | $299 a month | — |
| 5 mg | $399 a month | — |
| 7.5 mg | $449 a month | $499 |
| 10 mg | $449 a month | $699 |
| 12.5 mg | $449 a month | $699 |
| 15 mg | $449 a month | $699 |
Page dated September 2, 2026. Needles and syringes for vials are extra. The single-dose pen is not sold self-pay; with commercial insurance it's "as low as $25."11
Where to buy
| Option | Form | Price | Link |
|---|---|---|---|
| LillyDirect, Zepbound | Single-dose vial or multi-dose KwikPen | $299 to $449 a month by dose11 | Visit |
| LillyDirect, Mounjaro | Single-dose pen | $499 a month, all doses (page dated October 14, 2026)12 | Visit |
| Retail pharmacy, with insurance | Any labeled form | Depends on your plan | — |
Price history
- December 1, 2025. Zepbound vial prices cut from $349, $499 and $499 to $299, $399 and $449.42
- November 6, 2025. In an agreement with the US government, Lilly agreed to price the Zepbound multi-dose pen at $299 to $449 on LillyDirect, said Medicare beneficiaries would pay no more than $50 a month from as early as April 1, 2026, and said self-pay Mounjaro would be priced 50% to 60% below list.43
- List price. GoodRx put Zepbound's list price at $499 to $1,086 per 28 days as of Jan 2026.44 Lilly's own pricing page didn't show a figure when checked, so the current list prices of Zepbound and Mounjaro are Unverified.
Your own doctor and insurance
Any licensed prescriber can write a prescription for Mounjaro or Zepbound, and you can fill it at a retail pharmacy. Coverage depends on your plan and your diagnosis, such as type 2 diabetes, obesity or sleep apnea. Ask your plan which brand it covers and whether it needs prior authorization.
Compounded and research tirzepatide
We don't list sellers. The shortage that allowed routine compounding ended in 2024, and "research use only" products skip the prescription, the pharmacy and FDA review. Details
Legal status history
Current status first, then newest to oldest.
- Current statusFDA-approved as Mounjaro and Zepbound. Routine compounding of copies ended with the shortage. FDA's Apr 30, 2026 proposal to keep tirzepatide off the 503B bulks list has no final action that we found4; see the regulatory tracker.
- Import Alert 66-80 on bulk GLP-1 ingredients, including tirzepatide, revised.32
- Mounjaro approved to lower the risk of major heart events in adults with type 2 diabetes at high risk.2
- Fifth Circuit upholds FDA's tirzepatide shortage decision (No. 25-10600, unpublished).3
- Europe's regulator adds SURPASS-CVOT data to Mounjaro's product information without a separate heart indication.45
- FDA proposes excluding tirzepatide, semaglutide and liraglutide from the 503B bulks list.4
- FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s, saying compounded drugs are not the same as generics.31
- Zepbound label adds a severe stomach and bowel reactions warning and removes the suicidal behavior and ideation warning.6
- Europe's regulator declines a separate heart-failure indication for Mounjaro.21
- Mounjaro multi-dose vials on the market.14
- Mounjaro label adds children 10 and older with type 2 diabetes, and a severe stomach and bowel reactions warning.8, 16
- Zepbound vial self-pay prices cut.42
- Lilly pricing agreement with the US government.43
- FDA issues Import Alert 66-80 on bulk GLP-1 ingredients.33
- Lilly withdraws its US heart-failure application.9
- Grace period ends for outsourcing facilities (503B). Pharmacies (503A) had until Feb 18.1
- Zepbound approved for moderate-to-severe obstructive sleep apnea with obesity.19
- FDA confirms the tirzepatide shortage is resolved after re-evaluation.1
- FDA first finds the tirzepatide shortage resolved.1
- Zepbound approved for chronic weight management.18
- Mounjaro approved for type 2 diabetes, the first drug to activate both GIP and GLP-1 receptors.15
FAQ
Is Mounjaro the same drug as Zepbound?
Yes, both are tirzepatide at the same doses. Mounjaro is approved for type 2 diabetes and for lowering heart risk in type 2 diabetes. Zepbound is approved for weight management and for sleep apnea with obesity.
How much weight do people lose?
In SURMOUNT-1, people without diabetes lost 15.0% to 20.9% over 72 weeks, depending on dose, vs 3.1% on placebo. People with type 2 diabetes lost less: 12.8% to 14.7% in SURMOUNT-2. Results vary widely between people.
Does it work better than semaglutide?
For weight, yes in the one head-to-head trial: 20.2% vs 13.7% over 72 weeks in SURMOUNT-5. Semaglutide has more approved uses and comes as a pill.
Is compounded tirzepatide legal now?
Routine copies aren't. The shortage ended in 2024, and the Fifth Circuit upheld FDA's decision in Aug 2026. Compounded drugs are not FDA-approved and are not generics.
Is there a tirzepatide pill?
No. Every labeled form is a weekly injection.
Is it approved for heart failure?
No. Lilly withdrew the US application after FDA asked for another trial. The Aug 2026 heart approval covers lowering heart attack, stroke and heart death risk in type 2 diabetes.
What happens if I stop?
Most people regain weight. In SURMOUNT-4, those switched to placebo regained 14.0% of body weight within a year.
Can children take it?
Mounjaro is approved for type 2 diabetes in children 10 and older, at up to 10 mg weekly. Zepbound's weight indication is for adults.
How much does it cost without insurance?
On LillyDirect, Zepbound vials or KwikPen cost $299 to $449 a month by dose if you refill within 45 days, and Mounjaro costs $499 a month. You need a prescription either way.
Can I take it with Ozempic or Wegovy?
The Zepbound label says using it with any GLP-1 receptor agonist, which includes semaglutide, is not recommended. Switching is a prescriber's call.
References
45 sources, with links
- Pharmacy Times. FDA affirms tirzepatide shortage resolved, sets transition period for compounding (Dec 2024). Link
- Eli Lilly. FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk (Aug 28, 2026). Link
- US Court of Appeals for the Fifth Circuit. Outsourcing Facilities Ass'n v. FDA, No. 25-10600 (tirzepatide), unpublished (Aug 27, 2026). PDF
- Pharmacy Times. FDA moves to permanently close the door on compounded GLP-1s (May 1, 2026; on FDA's Apr 30, 2026 proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list). Link
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM 2022;387:205–16. Ovid
- FDA. Zepbound (tirzepatide) prescribing information, revised 04/2026. PDF
- American College of Cardiology journal scan. SURMOUNT-5 (Aronne, NEJM 2025;393:26–36; Jul 10, 2025). Link
- FDA. Mounjaro (tirzepatide) prescribing information, revised 08/2026. PDF
- ConscienHealth. Lilly withdraws tirzepatide application to FDA for heart failure (May 3, 2025). Link
- TCTMD. SURPASS-CVOT published: large trial confirms CVD efficacy of tirzepatide (Nicholls, NEJM 2025;393:2409–20). Link
- LillyDirect. Zepbound self-pay pricing (page dated Sep 2, 2026; checked Nov 1, 2026). Link
- LillyDirect. Mounjaro self-pay pricing (page dated Oct 14, 2026; checked Nov 1, 2026). Link
- Wikipedia. Tirzepatide (infobox identifiers; secondary source). Link
- FDA FDALabel. Mounjaro structured product label, version 40 (effective Aug 27, 2026; product listing). fda.gov
- BioSpace (FDA release). FDA approves novel, dual-targeted treatment for type 2 diabetes (May 13, 2022). Link
- FDA. Mounjaro multidisciplinary review, pediatric type 2 diabetes (PDUFA goal date Dec 19, 2025). fda.gov
- Pediatric Endocrine Society. New drugs and therapeutics update: Mounjaro (tirzepatide) approved in pediatrics (Feb 24, 2026). Link
- BioSpace (FDA release). FDA approves new medication for chronic weight management (Nov 8, 2023). Link
- FDA. FDA approves first medication for obstructive sleep apnea (Dec 20, 2024). fda.gov
- Drugs.com. Zepbound FDA approval history (secondary source). Link
- European Medicines Agency. Questions and answers: outcome of assessment of Mounjaro for heart failure with preserved ejection fraction (Jan 30, 2026). PDF
- American College of Cardiology. SURMOUNT-2 trial summary (Garvey, Lancet 2023). Link
- Wadden TA et al. Tirzepatide after intensive lifestyle intervention (SURMOUNT-3). Nat Med 2023;29:2909–18 (PMID 37840095). Citation
- Eli Lilly release (via BioSpace). SURMOUNT-3 and SURMOUNT-4 results (Jul 27, 2023). Link
- ACG Evidence-Based GI. SURMOUNT-4 (Aronne, JAMA 2024). Link
- American College of Cardiology. SURMOUNT-OSA trial summary (Malhotra, NEJM 2024;391:1193–205). Link
- American College of Cardiology. SUMMIT trial summary (Packer, NEJM 2024). Link
- AJMC. Complete data show tirzepatide brings greater A1C reduction, weight loss than semaglutide (SURPASS-2; Jun 25, 2021). Link
- GPnotebook. SURPASS-2: tirzepatide versus semaglutide once weekly in type 2 diabetes. Link
- HCPLive. SURPASS-PEDS: tirzepatide achieves superiority to placebo in adolescent type 2 diabetes (Sep 18, 2025). Link
- FDA. FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s (Mar 3, 2026). fda.gov
- FDA. Import Alert 66-80, detention of GLP-1 bulk drug substances (revised Oct 9, 2026). fda.gov
- Frier Levitt. FDA issues import alert on GLP-1s following launch of Green List (Sep 2025). Link
- FDA. Wegovy (semaglutide) injection and tablets, prescribing information, revised 05/2026. PDF
- Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial. Lancet 2023 (online Jun 26, 2023). doi:10.1016/S0140-6736(23)01053-X. Author PDF
- Eli Lilly press release (via BioSpace). TRIUMPH-2 and TRIUMPH-3 topline results; BLA submission planned for Q1 2027 (Jul 23, 2026). Link
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. NEJM 2023 (online Jun 26, 2023). doi:10.1056/NEJMoa2301972. Author PDF
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM 2021;384:989–1002. Abstract: J Endocr Soc 2021;5(Suppl 1):A10. PMC8089593
- Jastreboff AM, Kaplan LM, Davies MJ et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1). NEJM, published online Sep 29, 2026. doi:10.1056/NEJMoa2604169. Summary: GPnotebook
- Eli Lilly press release. TRANSCEND-T2D-2: retatrutide vs Ozempic 2 mg, topline results (Oct 28, 2026). Not peer reviewed. Link
- TheNNT. Efficacy of tirzepatide, retatrutide and semaglutide for weight loss in obese individuals without diabetes (review of Moiz et al.). Link
- BioSpace. Lilly cuts Zepbound prices again when buying through DTC program (Dec 1, 2025). Link
- Eli Lilly. Agreement with the US government on pricing (Nov 6, 2025). Link
- GoodRx. How much does Zepbound cost? (updated May 18, 2026; secondary source). Link
- European Medicines Agency. Outcome of assessment of Mounjaro to reduce the risk of serious events affecting the heart and blood circulation (Jun 26, 2026). PDF
This page is for education and is not medical advice. Tirzepatide is a prescription drug. Talk to a clinician before starting, stopping or changing any dose.